Compile Data Set for Download or QSAR
Report error Found 451 Enz. Inhib. hit(s) with Target = 'Potassium channel subfamily K member 9'
TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM458963((4-{[2-(4-Bromophenyl)imidazo[,2-a]pyridin-3-yl]me...)
Affinity DataIC50: 1.04nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532051(US11208422, Example 12 | 3-{[2-(4-Chlorophenyl)imi...)
Affinity DataIC50: 1.10nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532241(US11208422, Example 83 | US11208422, Example 82)
Affinity DataIC50: 1.40nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM515603(US11098063, Example 109)
Affinity DataIC50: 1.5nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532228(US11208422, Example 88 | US11208422, Example 89 | ...)
Affinity DataIC50: 1.60nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM515513(US11098063, Example 29 | (3-Chloro-6-methoxypyridi...)
Affinity DataIC50: 1.80nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532162(US11208422, Example 14 | 3-{[2-(4-Chlorophenyl)imi...)
Affinity DataIC50: 2.20nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM458968(US10759794, Example 47)
Affinity DataIC50: 2.30nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532051(US11208422, Example 12 | 3-{[2-(4-Chlorophenyl)imi...)
Affinity DataIC50: 2.5nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532051(US11208422, Example 12 | 3-{[2-(4-Chlorophenyl)imi...)
Affinity DataIC50: 2.5nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532229(US11208422, Example 91 | US11208422, Example 90 | ...)
Affinity DataIC50: 2.80nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM459034(US10759794, Example 72)
Affinity DataIC50: 3nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532179(US11208422, Example 38 | US11208422, Example 27)
Affinity DataIC50: 3nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM515512(US11098063, Example 28 | (3-Fluoro-6-methoxypyridi...)
Affinity DataIC50: 3.20nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532179(US11208422, Example 38 | US11208422, Example 27)
Affinity DataIC50: 4nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532173(US11208422, Example 32 | US11208422, Example 21)
Affinity DataIC50: 4.10nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM515509(US11098063, Example 21 | (3-Chloro-6-methoxypyridi...)
Affinity DataIC50: 4.20nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532181(US11208422, Example 40 | US11208422, Example 29)
Affinity DataIC50: 4.40nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532162(US11208422, Example 14 | 3-{[2-(4-Chlorophenyl)imi...)
Affinity DataIC50: 4.5nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM413565(US10414765, Example 49)
Affinity DataIC50: 4.60nMAssay Description:In Vitro Electrophysiological Analysis of the Human TASK-1 and TASK-3 Channels Via Two-Electrode Voltage Clamp Technique in Xenopus laevis OocytesSub...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
8/2/2020
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM515584(US11098063, Example 84)
Affinity DataIC50: 4.60nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532229(US11208422, Example 91 | US11208422, Example 90 | ...)
Affinity DataIC50: 4.70nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM515579(US11098063, Example 78 | US11098063, Example 77)
Affinity DataIC50: 4.90nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532232(US11208422, Example 73)
Affinity DataIC50: 5nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532237(US11208422, Example 79 | US11208422, Example 78)
Affinity DataIC50: 5nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532231(US11208422, Example 72)
Affinity DataIC50: 5.10nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM459030((4-{[2-(4-Chlorophenyl)imidazo[1,2-a]pyridin-3-yl]...)
Affinity DataIC50: 5.20nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM515530(US11098063, Example 22 | (3-{[2-(4-Chlorophenyl)im...)
Affinity DataIC50: 5.20nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532229(US11208422, Example 91 | US11208422, Example 90 | ...)
Affinity DataIC50: 5.5nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532180(US11208422, Example 39 | US11208422, Example 28)
Affinity DataIC50: 5.60nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM458967(US10759794, Example 39)
Affinity DataIC50: 6.20nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM515512(US11098063, Example 28 | (3-Fluoro-6-methoxypyridi...)
Affinity DataIC50: 6.60nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532178(US11208422, Example 37 | US11208422, Example 26)
Affinity DataIC50: 6.90nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532166([3-{[2-(5-Chloropyridin-2-yl)imidazo[1,2-a]pyridin...)
Affinity DataIC50: 7.30nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM515566(US11098063, Example 64)
Affinity DataIC50: 8.40nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM515528(US11098063, Example 18 | (3-Fluoro-6-methoxypyridi...)
Affinity DataIC50: 8.60nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM515515(US11098063, Example 51)
Affinity DataIC50: 8.70nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM459036(US10759794, Example 74)
Affinity DataIC50: 9.10nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532239(US11208422, Example 81 | US11208422, Example 80)
Affinity DataIC50: 9.20nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM459029((4-{[2-(4-Chlorophenyl)imidazo [1,2-a]pyridin-3-yl...)
Affinity DataIC50: 9.40nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Rat)
Universidad De Talca

Curated by ChEMBL
LigandPNGBDBM50426570(CHEMBL2324344)
Affinity DataIC50: 10nMAssay Description:Inhibition of rat TASK3 expressed in (FRT) epithelial cells by chamber based electrophysiology assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/18/2021
Entry Details Article
PubMed
TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM459008(US10759794, Example 43)
Affinity DataIC50: 10nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM515511((5-Cyclopropyl-1,3-oxazol-4-yl)(5-{[2-(4-isopropyl...)
Affinity DataIC50: 10nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM459031((4-{[2-(4-Cyclopropylphenyl)imidazo[1,2-a]pyridin-...)
Affinity DataIC50: 11nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532174(US11208422, Example 25 | US11208422, Example 22)
Affinity DataIC50: 11nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532237(US11208422, Example 79 | US11208422, Example 78)
Affinity DataIC50: 11nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM515526(US11098063, Example 16 | (7-{[2-(4-Chlorophenyl)im...)
Affinity DataIC50: 12nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM515552(US11098063, Example 49)
Affinity DataIC50: 12nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM532162(US11208422, Example 14 | 3-{[2-(4-Chlorophenyl)imi...)
Affinity DataIC50: 12nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were conducted using stably transfected CHO cells. The compounds o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2022
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM459007(US10759794, Example 42)
Affinity DataIC50: 13nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

Displayed 1 to 50 (of 451 total ) | Next | Last >>
Jump to: